-$0.67 Earnings Per Share Expected for Aquestive Therapeutics Inc (NASDAQ:AQST) This Quarter

Equities analysts expect that Aquestive Therapeutics Inc (NASDAQ:AQST) will post earnings of ($0.67) per share for the current quarter, Zacks reports. Two analysts have made estimates for Aquestive Therapeutics’ earnings, with estimates ranging from ($0.72) to ($0.61). Aquestive Therapeutics posted earnings per share of ($1.90) in the same quarter last year, which indicates a positive year-over-year growth rate of 64.7%. The firm is expected to announce its next earnings report on Tuesday, September 3rd.

According to Zacks, analysts expect that Aquestive Therapeutics will report full year earnings of ($2.57) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($2.25). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.73) per share, with EPS estimates ranging from ($1.87) to ($1.58). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Aquestive Therapeutics.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10). The company had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.66 million.

Several equities analysts recently issued reports on AQST shares. BMO Capital Markets lowered their price target on Aquestive Therapeutics from $24.00 to $21.00 and set an “outperform” rating on the stock in a research note on Friday, March 15th. Wedbush set a $31.00 price target on Aquestive Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 8th. HC Wainwright started coverage on Aquestive Therapeutics in a research note on Monday, April 22nd. They set a “buy” rating and a $10.00 price target on the stock. Finally, Zacks Investment Research upgraded Aquestive Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research note on Thursday, March 21st. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $19.54.

Several hedge funds have recently added to or reduced their stakes in AQST. Vanguard Group Inc. bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $8,055,000. New York State Common Retirement Fund bought a new stake in shares of Aquestive Therapeutics in the 4th quarter valued at approximately $28,000. BlackRock Inc. grew its stake in shares of Aquestive Therapeutics by 36.1% in the 4th quarter. BlackRock Inc. now owns 641,800 shares of the company’s stock valued at $4,042,000 after purchasing an additional 170,396 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Aquestive Therapeutics by 56.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 473,930 shares of the company’s stock valued at $2,986,000 after purchasing an additional 170,984 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Aquestive Therapeutics in the 4th quarter valued at approximately $108,000. Institutional investors own 66.21% of the company’s stock.

AQST traded up $0.04 on Friday, hitting $4.13. 2,056 shares of the stock traded hands, compared to its average volume of 116,369. Aquestive Therapeutics has a 52 week low of $3.65 and a 52 week high of $20.70. The company has a quick ratio of 1.71, a current ratio of 1.89 and a debt-to-equity ratio of 4.23. The company has a market cap of $98.40 million and a price-to-earnings ratio of -1.48. The business has a fifty day moving average of $4.38.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.